XBiotech (XBIT) Cash from Financing Activities (2014 - 2025)
XBiotech (XBIT) posted quarterly Cash from Financing Activities of -$10.2 million for Q1 2025, down 201.94% year-over-year from $10.1 million in Q1 2024, and down 3721.91% quarter-over-quarter from $283000.0 in Q4 2024.
XBiotech (XBIT) Cash from Financing Activities (2014 - 2025) Analysis & Trends
XBiotech's Cash from Financing Activities history runs 11 years deep, the most recent figure standing at -$10.2 million for Q1 2025.
- In Q1 2025, Cash from Financing Activities fell 201.94% year-over-year to -$10.2 million; the TTM figure through Dec 2025 stood at -$10.2 million (down 198.09% YoY), while the FY2025 annual figure was -$10.2 million, down 198.09% from the prior year.
- Cash from Financing Activities for Q1 2025 stood at -$10.2 million, down from $283000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $10.1 million in Q1 2024, with the low at -$72.0 million in Q3 2021.
- The 4-year median for Cash from Financing Activities is $48000.0 (2024), against an average of -$6.1 million.
- Peak annual rise in Cash from Financing Activities reached 1330.22% in 2021, while the deepest fall reached 3330.45% in 2021.
- XBiotech's Cash from Financing Activities stood at $33000.0 in 2021, then plunged by 84.85% to $5000.0 in 2023, then jumped by 5560.0% to $283000.0 in 2024, then slumped by 3721.91% to -$10.2 million in 2025.
- Business Quant data shows XBIT's Cash from Financing Activities at -$10.2 million in Q1 2025, $283000.0 in Q4 2024, and $64000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | XBiotech | 69.51 Mn | 69.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -10.25 Mn |
| Mar 31, 2025 | -10.25 Mn |
| Dec 31, 2024 | 283,000.00 |
| Dec 31, 2024 | 283,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 48,000.00 |
| Jun 30, 2024 | 48,000.00 |
| Mar 31, 2024 | 10.06 Mn |
| Mar 31, 2024 | 10.06 Mn |
| Sep 30, 2023 | 5,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -14,000.00 |
| Jun 30, 2023 | -14,000.00 |
| Dec 31, 2021 | 33,000.00 |
| Dec 31, 2021 | 33,000.00 |
| Sep 30, 2021 | -72.04 Mn |
| Sep 30, 2021 | -72.04 Mn |
| Jun 30, 2021 | 3.98 Mn |
| Jun 30, 2021 | 3.98 Mn |